- A branded ingredient can add real value: a precise identity, specifications, a process, traceability and sometimes studies carried out directly on that material.
- A ® symbol or a patent does not prove superior efficacy. Dose, study quality and relevance to the finished product still matter.
- A non-branded ingredient can be excellent. You simply have to build its evidence without borrowing that of another proprietary material.
ExceptionHYAL® Star. Quali®-C. Reggenerate™.
Then, a few lines lower down: saffron extract.
Why do some ingredients arrive with a name, a logo and sometimes their own website, while others remain anonymous?
And above all: does an ingredient become better the day you add a trademark?
Of course not.
But a good proprietary ingredient can provide something genuinely useful: precision.
The first advantage: knowing exactly what you are buying
“Hyaluronic acid” describes a category.
“ExceptionHYAL® Star” describes a specific material, with a supplier, a molecular profile and specifications.
That difference becomes valuable when you read a study.
If the publication tests exactly the material you use, the scientific link is much more direct than if it simply concerns an ingredient with the same generic name.
It can make it easier to answer the question: “is this actually the same material as the one in the study?”. That improves traceability; it is not an automatic guarantee of results.
ExceptionHYAL® Star is our simplest example
A trial published in 2021 evaluated 200 mg per day of full-spectrum hyaluronan ExceptionHYAL® Star for 28 days in 60 women.
In our Hyaluronic Acid 200 mg formula, we use 224.8 mg of the raw material to provide 200 mg of hyaluronic acid.
The link between the material studied and the material used is therefore clear.
But the study remains an ingredient study. It is not a clinical study of the finished Eclo product with its vitamin C and dosage form.
Second advantage: specifications that stay consistent
A clinical study tests a material at a given point in time.
If that material changes dramatically from batch to batch, the publication becomes less useful for future batches.
This is particularly true for plants and complex biological matrices.
A good proprietary supplier can therefore provide stable specifications: identity, content, purity, contaminants, process and traceability.
That is less photogenic than a wrinkle percentage. Yet it is what makes repeatability possible.
Quali®-C shows that premium can be industrial
Vitamin C is still ascorbic acid.
Using Quali®-C does not change its physiology.
The value can lie elsewhere: manufacturing origin, impurity control, documentation, stability, regulatory support and traceability.
In other words, a material can be better to source and control without becoming a “super vitamin C” inside the body.
And the patent? Useful, but not as clinical proof
A patent can protect a process, a composition or an application.
It can signal genuine innovation work.
But patented does not mean clinically superior.
To demonstrate a result in humans, you still have to go back to human trials.
A signal of innovation or intellectual property.
A different question, with a different method.
Reggenerate™ highlights a very important rule
Reggenerate™ is an eggshell-membrane material developed by Circul'Egg.
The supplier documents a matrix that naturally contains several components, including collagen, elastin, hyaluronic acid and glycosaminoglycans.
Trials exist on other proprietary membranes such as Ovoderm or MKARE®.
They do not become trials of Reggenerate™.
The proprietary name is useful precisely because it lets us distinguish one material from another. It would be strange to forget that only when a neighbouring ingredient’s study happens to suit us.
What about a non-branded ingredient?
It can be perfectly premium.
Our saffron is a good example: an extract of Crocus sativus stigmas, standardised and supplied to its own specifications.
What it does not have is a public identity that lets us directly connect a trial to this exact material.
So we have to adapt our language. We can talk about its quality, standardisation and role in the formula. We cannot claim affron® or Safr'Inside™ studies as if they had tested our extract.
“Clinically studied” is much weaker than it sounds
A material may have been studied in 20 people, at twice the dose used in the product being sold, on a secondary endpoint or in a formula containing five other actives.
And the phrase “clinically studied” will still be literally true.
That is why we prefer to ask: what did the study show, on what, at what dose and with what limitations?
Our checklist before paying a supplier premium
At Eclo: no logo collection
Ressource™ uses ExceptionHYAL® Star, Céramosides™ and a TRAACS® bisglycinate, among other ingredients.
Collagen uses Reggenerate™ and Quali®-C.
We choose proprietary materials when they provide real precision or greater control.
And we keep non-branded materials when they meet the specification.
Premium is therefore an ingredient-by-ingredient decision, not a doctrine.
The real luxury is not having the most ® symbols on the label. It is being able to explain why each material deserves its place.
The brand name comes after the material.
Process, specifications, dose, traceability and data: that is the dossier we care about. The logo is simply a way to identify it.
Discover the formulasSources
Ribnicky D.M. et al. (2008). Evaluation of botanicals for improving human health. American Journal of Clinical Nutrition.
PubMed, PMID 18258641
van Breemen R.B., Fong H.H.S., Farnsworth N.R. (2007). The role of quality assurance and standardization in the safety of botanical dietary supplements. Chemical Research in Toxicology.
PubMed, PMID 17362032
Michelotti A. et al. (2021). Oral intake of a new full-spectrum hyaluronan improves skin profilometry and ageing: a randomized, double-blind, placebo-controlled clinical trial. European Journal of Dermatology.
PubMed, PMID 34933842
ROELMI HPC, Circul'Egg and dsm-firmenich.
Official documentation for the raw materials cited, used to characterise the ingredients and not as a substitute for independent clinical trials.
